ZAZainab Arif

Zainab Arif

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zainab Arif has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dexamethasone versus triamcinolone acetonide for the management of postoperative inflammation following cataract surgery

    by Humayou Ahmed, Muhammad Saad Khan, Zauha Fawad Memon, Serish Bano, Samreen Shahid, Zainab Arif, Syed Ali Hassan, Umarah Lutuf, Wajeeha, Shifa, et al.

    Background: Cataract remains the leading cause of reversible blindness worldwide, particularly in low-resource settings. Effective control of postoperative inflammation is essential to prevent complications such as cystoid macular edema and raised intraocular pressure. Dexamethasone and Triamcinolone acetonide (TCA) are widely used corticosteroids; however, their comparative efficacy remains uncertain. This updated systematic review and meta-analysis aimed to compare their effectiveness following cataract surgery. Methods: A systematic search of 4 databases (PubMed, Google Scholar, Cochrane Central Library and Scopus) was conducted up to June 2026 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (International Prospective Register of Systematic Reviews: CRD420261435380). Randomized controlled trials and prospective studies comparing dexamethasone and TCA in adults undergoing phacoemulsification were included. Risk of bias was assessed using cochrane risk of bias 2 and the Newcastle–Ottawa Scale. Certainty of evidence was evaluated using grading of recommendations assessment, development and evaluation. A random-effects model was used, with heterogeneity assessed by I 2 . Results: Twelve studies (nine randomized controlled trials and 3 non-randomized prospective studies; n = 2003) were included. No significant differences were observed in intraocular pressure (Mean Difference, mm Hg) at any time point up to 3 months. Visual acuity showed modest improvement with TCA at 7 and 28/30 days, though results were inconsistent on sensitivity analysis. No significant differences were found in anterior chamber flare or cells across all time points. A nonsignificant trend toward greater endothelial cell loss was observed with dexamethasone. Overall, evidence certainty was low. Conclusion: Dexamethasone and TCA demonstrate comparable efficacy and safety in controlling postoperative inflammation after cataract surgery. TCA may offer short-term visual benefits and prolonged action, whereas dexamethasone allows flexible dosing. Clinical decisions should be individualized, considering patient compliance and clinical context.

  • Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs

    by Amna Amir Jalal, Shaikh Muhammad Daniyal, Zainab Arif, Erum Siddiqui, Syed Ibad Hussain, Fatima Qazi, Muhammad Burhan

    Objective: To evaluate the efficacy and safety of oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with hypercholesterolemia and assess their potential as a convenient alternative to injectable therapies. Data Sources: PubMed, Embase, Scopus, and CENTRAL were searched from inception to May 10th, 2026, using terms related to oral PCSK9 inhibitors and hypercholesterolemia. The study was registered with PROSPERO (CRD420261329028). Study Selection and Data Extraction: Randomized controlled trials (RCTs) comparing oral PCSK9 inhibitors with placebo in adults receiving background lipid-lowering therapy were included. Two reviewers independently screened studies and extracted data on an Excel sheet. Data Synthesis: Five RCTs were analyzed. Oral PCSK9 inhibitors significantly reduced LDL cholesterol (mean difference [MD] −52.15 mg/dL; 95% CI −59.42 to −44.87), apolipoprotein B (MD −42.85 mg/dL; 95% CI −49.52 to −36.18), and lipoprotein(a) (MD −35.11 mg/dL; 95% CI −52.86 to −17.36) compared with placebo. Significant reductions were also observed in triglycerides and total cholesterol. Safety outcomes were comparable to placebo, with no increased risk of adverse events (risk ratio [RR] 1.04; 95% CI 0.98-1.09) or serious adverse events. Subgroup analyses indicated enhanced efficacy with enlicitide and specific dosing regimens. Relevance to Patient Care and Clinical Practice: Oral PCSK9 inhibitors address major barriers inherent to injectable biologics. By eliminating needle-related anxiety, injection-site reactions, and the logistical burdens of cold-chain storage, these agents may significantly improve patient adherence and satisfaction. This transition to a convenient oral regimen facilitates integration into standard care, potentially expanding access for patients reluctant to maintain long-term injectable therapy. Conclusions: Oral PCSK9 inhibitors significantly improve atherogenic lipid profiles and are well tolerated. They represent a promising and convenient alternative to injectable PCSK9 inhibitors for managing hypercholesterolemia.


  • Open Access

    Safety and Efficacy of Obinutuzumab in Treating Lupus Nephritis: A Systematic Review

    by Zainab Arif, Hafsa Ali, Erum Siddiqui, Shorrem Naeem, Mohammed Hammad Jaber Amin

    Background: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), often leading to end‐stage renal disease. Despite current immunosuppressive therapies, complete renal remission remains limited. Obinutuzumab, a type II anti‐CD20 monoclonal antibody, offers enhanced B‐cell depletion compared to type I antibodies and may improve renal outcomes in LN. This systematic review evaluates the efficacy and safety of obinutuzumab in treating adult patients with proliferative LN. Methods: This review was registered with PROSPERO (CRD420251074418) and conducted in accordance with the PRISMA guidelines. A comprehensive search of PubMed, Cochrane, Embase, Scopus, and clinical trial registries was conducted through June 2025. Eligible studies were randomized controlled trials (RCTs) comparing obinutuzumab vs. placebo in adult patients with biopsy‐confirmed active LN. Primary outcomes included complete renal response (CRR), proteinuria, and estimated glomerular filtration rate (eGFR). Secondary outcomes included immunological markers and adverse events. Data were synthesized qualitatively due to the limited available trials. Results: Two RCTs (REGENCY 2025 and NOBILITY 2022) with 396 patients met the inclusion criteria. Obinutuzumab significantly improved CRR (46.4% in REGENCY at week 76; 41% in NOBILITY at week 104) and reduced proteinuria (UPCR < 0.5 in 62% vs. 37% in controls). Improvements in eGFR, complement levels (C3 and C4), and anti‐dsDNA titers were also noted. Adverse events occurred at similar rates across groups, although serious infections and infusion reactions were somewhat higher in one trial. No significant increase in mortality was observed. Conclusion: Obinutuzumab appears to be a promising therapy for proliferative LN, offering enhanced renal response and immunological benefits. Its potential for long‐term renal protection and steroid‐sparing effects supports further investigation through large‐scale comparative trials.

  • Open Access

    Orexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 1

    by Zainab Arif, Erum Siddiqui, Syeda Fadak Zahra Hujjat, Muhammad Saad Khan, Abubakr Mauhmoud

    Narcolepsy type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, and disturbed nocturnal sleep, resulting from the loss of hypothalamic neurons that produce orexin. Current therapies, including stimulants, antidepressants, and sodium oxybate, primarily offer symptomatic relief without addressing the underlying orexin deficiency and often have safety or adherence limitations. Orexin receptor 2 (OX2R) agonists represent a novel therapeutic strategy aimed at restoring physiological wakefulness by directly targeting the core neurochemical deficit. TAK-994, the first oral OX2R agonist, demonstrated remarkable efficacy in reducing cataplexy and improving wakefulness but was discontinued due to dose-dependent hepatotoxicity. TAK-861 (oveporexton), a next-generation OX2R agonist with improved structural properties, has shown encouraging Phase 2 results with comparable efficacy and a favorable safety profile, including minimal hepatic effects and once-daily dosing convenience. If validated in large-scale Phase 3 studies, TAK-861 could become the first disease-modifying therapy for NT1, representing a paradigm shift from symptomatic management to mechanism-based treatment. The ongoing development of OX2R agonists highlights a promising frontier in precision sleep medicine, offering renewed hope for patients by targeting orexin restoration.